Compugen Ausschüttungen und Rückkäufe

Zukünftiges Wachstum Kriterienprüfungen 0/6

Compugen hat in der Vergangenheit keine Dividende gezahlt.

Wichtige Informationen

n/a

Dividendenausschüttung

-1.8%

Rückkaufsrendite

Gesamte Aktionärsrendite	-1.8%
Zukünftige Dividendenrendite	n/a
Wachstum der Dividende	n/a
Nächster Dividendenzahlungstermin	n/a
Ex-Dividendendatum	n/a
Dividende pro Aktie	n/a
Ausschüttungsquote	n/a

Jüngste Updates zu Dividenden und Rückkäufen

Keine Aktualisierungen

Recent updates

Investors Aren't Buying Compugen Ltd.'s (NASDAQ:CGEN) Revenues

Aug 22

Analysts Have Been Trimming Their Compugen Ltd. (NASDAQ:CGEN) Price Target After Its Latest Report

May 22

Why Investors Shouldn't Be Surprised By Compugen Ltd.'s (NASDAQ:CGEN) 25% Share Price Plunge

May 01

Is Compugen Ltd. (NASDAQ:CGEN) Trading At A 36% Discount?

Apr 05

Compugen Ltd.'s (NASDAQ:CGEN) Price Is Right But Growth Is Lacking After Shares Rocket 26%

Mar 08

Here's Why We're Not Too Worried About Compugen's (NASDAQ:CGEN) Cash Burn Situation

Mar 04

Companies Like Compugen (NASDAQ:CGEN) Are In A Position To Invest In Growth

Sep 21

Compugen appoints Alberto Sessa as CFO

Sep 12

Compugen gets Japanese patent for COM701, anti-PVRIG antibodies

Aug 24

Compugen Q2 2022 Earnings Preview

Aug 03

Companies Like Compugen (NASDAQ:CGEN) Are In A Position To Invest In Growth

Jun 23

Companies Like Compugen (NASDAQ:CGEN) Are In A Position To Invest In Growth

Mar 02

Here's Why We're Not Too Worried About Compugen's (NASDAQ:CGEN) Cash Burn Situation

Nov 04

Shareholders Will Probably Not Have Any Issues With Compugen Ltd.'s (NASDAQ:CGEN) CEO Compensation

Aug 27

Companies Like Compugen (NASDAQ:CGEN) Can Afford To Invest In Growth

Jun 28

Compugen gains on takeover speculation after iTeos Therapeutics deal

Jun 14

Compugen reports updated COM701 data from Phase 1 study at ASCO21

Jun 08

Compugen's COM902 demonstrates potential benefit in cancer

Apr 27

Here's Why We're Not At All Concerned With Compugen's (NASDAQ:CGEN) Cash Burn Situation

Mar 15

Are Institutions Heavily Invested In Compugen Ltd.'s (NASDAQ:CGEN) Shares?

Feb 08

A Look At The Fair Value Of Compugen Ltd. (NASDAQ:CGEN)

Jan 04

Compugen earns $2M milestone under antibody development deal with AstraZeneca

Dec 23

Here's Why We're Not At All Concerned With Compugen's (NASDAQ:CGEN) Cash Burn Situation

Nov 30

Compugen Ltd. 2020 Q3 - Results - Earnings Call Presentation

Nov 08

Compugen: Speculative Play For Immuno-Oncology Exposure

Nov 07

Stabilität und Wachstum des Zahlungsverkehrs

Rufe Dividendendaten ab

Stabile Dividende: Es liegen keine ausreichenden Daten vor, um festzustellen, ob die Dividende je Aktie von CGEN in der Vergangenheit stabil war.

Wachsende Dividende: Unzureichende Daten, um festzustellen, ob die Dividendenzahlungen von CGEN gestiegen sind.

Dividendenrendite im Vergleich zum Markt

Compugen Dividendenrendite im Vergleich zum Markt

Wie sieht die Dividendenrendite von CGEN im Vergleich zum Markt aus?
Segment	Dividendenrendite
Unternehmen (CGEN)	n/a
Untere 25 % des Marktes (US)	1.4%
Markt Top 25 % (US)	4.3%
Branchendurchschnitt (Biotechs)	2.3%
Analystenprognose (CGEN) (bis zu 3 Jahre)	n/a

Bemerkenswerte Dividende: Es ist nicht möglich, die Dividendenrendite von CGEN im Vergleich zu den unteren 25 % der Dividendenzahler zu bewerten, da das Unternehmen keine aktuellen Ausschüttungen gemeldet hat.

Hohe Dividende: Es ist nicht möglich, die Dividendenrendite von CGEN im Vergleich zu den besten 25 % der Dividendenzahler zu bewerten, da das Unternehmen keine aktuellen Ausschüttungen gemeldet hat.

Gewinnausschüttung an die Aktionäre

Abdeckung der Erträge: Unzureichende Daten zur Berechnung der Ausschüttungsquote von CGEN, um festzustellen, ob die Dividendenzahlungen durch die Gewinne gedeckt sind.

Barausschüttung an die Aktionäre

Cashflow-Deckung: Es ist nicht möglich, die Nachhaltigkeit der Dividende zu berechnen, da CGEN keine Ausschüttungen gemeldet hat.

Compugen Ausschüttungen und Rückkäufe

Zukünftiges Wachstum Kriterienprüfungen 0/6

Wichtige Informationen

Jüngste Updates zu Dividenden und Rückkäufen

Recent updates

Forecast to breakeven in 2024

Compugen Ltd. to Present Anti-Tumor Activity and Safety Data of COM701, COM902 and Pembrolizumab Combination in Patients with Platinum Resistant Ovarian Cancer at SITC 2024

Compugen Ltd. to Report Q3, 2024 Results on Nov 12, 2024

Price target decreased by 25% to US$4.00

Investors Aren't Buying Compugen Ltd.'s (NASDAQ:CGEN) Revenues

New minor risk - Profitability

New major risk - Revenue and earnings growth

Forecast to breakeven in 2025

Compugen Ltd., Annual General Meeting, Sep 12, 2024

Compugen Ltd. Announces FDA Clearance of IND for Com503 for the Treatment of Solid Tumors

Compugen Ltd. to Report Q2, 2024 Results on Aug 06, 2024

Analysts Have Been Trimming Their Compugen Ltd. (NASDAQ:CGEN) Price Target After Its Latest Report

Compugen Ltd. Announces CFO Changes, Effective August 15, 2024

Compugen Ltd. to Report Q1, 2024 Results on May 20, 2024

Why Investors Shouldn't Be Surprised By Compugen Ltd.'s (NASDAQ:CGEN) 25% Share Price Plunge

Is Compugen Ltd. (NASDAQ:CGEN) Trading At A 36% Discount?

New minor risk - Shareholder dilution

Consensus revenue estimates increase by 41%, EPS downgraded

Now 23% undervalued

New major risk - Revenue and earnings growth

Compugen Ltd.'s (NASDAQ:CGEN) Price Is Right But Growth Is Lacking After Shares Rocket 26%

Compugen Ltd. to Report Q4, 2023 Results on Mar 05, 2024

Compugen (NASDAQ:CGEN) Is In A Good Position To Deliver On Growth Plans

Compugen Ltd. Announces Executive Changes

New major risk - Revenue and earnings growth

Consensus revenue estimates fall by 45%

Compugen Announces Receipt of Nasdaq Minimum Bid Price Notification

Compugen Ltd. Announces to Present New Data At Sitc 2023 Suggesting Leading Edge of Anti-Il18 Binding Protein Antibody, Com503, in Treating Cancer

Compugen Ltd. to Report Q3, 2023 Results on Nov 07, 2023

Will Compugen (NASDAQ:CGEN) Spend Its Cash Wisely?

Insufficient new directors

New major risk - Revenue and earnings growth

Consensus EPS estimates upgraded to US$0.31 loss

Compugen Ltd., Annual General Meeting, Sep 20, 2023

Compugen Ltd. to Report Q2, 2023 Results on Aug 07, 2023

Price target decreased by 7.0% to US$5.50

Compugen Ltd. Doses First Patient in Triple Immunotherapy Combination COM701, COM902 and Pembrolizumab Platinum Resistant Ovarian Cancer Proof-Of-Concept Study

Is Compugen (NASDAQ:CGEN) In A Good Position To Invest In Growth?

Compugen Regains Compliance with Nasdaq Minimum Bid Price Requirement

Price target increased by 15% to US$6.80

Here's Why We're Not Too Worried About Compugen's (NASDAQ:CGEN) Cash Burn Situation

Compugen Ltd. to Report Q4, 2022 Results on Feb 27, 2023

Compugen Ltd.'s COM701 (anti-PVRIG) in Dual and Triple Combination Demonstrates Preliminary Durable Anti-Tumor Activity and Immune Activation in Patients with Platinum Resistant Ovarian Cancer

Price target decreased to US$6.29

Compugen Demonstrates Preliminary Anti-Tumor Activity and Potent Immune Activation in Metastatic MSS-CRC Patients

Compugen Announces Receipt of Nasdaq Delisting Notice

Compugen Ltd. to Report Q3, 2022 Results on Nov 14, 2022

Companies Like Compugen (NASDAQ:CGEN) Are In A Position To Invest In Growth

Compugen Ltd. Announces Appointment of Alberto Sessa as Chief Financial Officer

Compugen appoints Alberto Sessa as CFO

Compugen gets Japanese patent for COM701, anti-PVRIG antibodies

Compugen Ltd. Announces Resignation of Ari Krashin as Chief Operating Officer in August 2022

Compugen Q2 2022 Earnings Preview

Compugen Ltd. to Report Q2, 2022 Results on Aug 04, 2022

Companies Like Compugen (NASDAQ:CGEN) Are In A Position To Invest In Growth

Compugen Announces CFO Departure

Compugen Ltd. to Report Q1, 2022 Results on May 16, 2022

Price target decreased to US$14.00

Companies Like Compugen (NASDAQ:CGEN) Are In A Position To Invest In Growth

Compugen Ltd. Announces Board Changes

Compugen Ltd. to Report Q4, 2021 Results on Feb 24, 2022

Price target decreased to US$18.57

Compugen Expands COM701 Intellectual Property Portfolio with New U.S. Patent Covering Triple Combination Use with anti-PD-1 and anti-TIGIT Antibodies

Here's Why We're Not Too Worried About Compugen's (NASDAQ:CGEN) Cash Burn Situation

Shareholders Will Probably Not Have Any Issues With Compugen Ltd.'s (NASDAQ:CGEN) CEO Compensation

Compugen Announces Bispecific Antibody Derived from COM902 to Enter Clinical Development

High number of new directors

Compugen Doses First Patient in Phase 1/2 Triple Combination Cohort Expansion of COM701 with Opdivo® and Bristol Myers Squibb's Anti-TIGIT Antibody, BMS-986207

Compugen Doses First Patient in Phase 1 Combination Study of COM902 and COM701 in Patients with Advanced Malignancies

Senior VP & Chief Medical Officer notifies of intention to sell stock

Compugen Doses First Patient in COM701/Opdivo® (nivolumab) Phase 1b Cohort Expansion Study

Compugen Ltd. Presents Research Supporting PVRIG as a Novel and Differentiated Checkpoint in the DNAM-1 Axis

Companies Like Compugen (NASDAQ:CGEN) Can Afford To Invest In Growth

Compugen gains on takeover speculation after iTeos Therapeutics deal

Compugen Ltd. Updates Data from Phase 1 Study of COM701